Recruiting
Phase 2
Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial
About this study
This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.
- Condition
- Prostate Cancer
- Tested
- HDR-Brachytherapy
- Sponsor
- University of Erlangen-Nürnberg Medical School
Who can join
- Age
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 13
- Minimum age: 18 years
- Eligible sex: Male
- Study condition: Prostate Cancer
- Age \> 18
- Histologically confirmed prostate cancer
- Gleason Score of index lesion ≤ 6 (3+3)
- Tumor stage: cT1-2a cN0 cM0
- Unilateral affection; index lesion ≤ 0.5ml with or without clinically non-significant lesion contralateral. No more than 25% of the punch should be affected. Therefore a 3D-TPM-biopsy is mandatory before treatment.
- PSA ≤ 10/ng/ml
- Prostate volume \< 60 m\^3
- No distant metastasis
- Life expectancy \> 10 years
- Informed consent
Exclusion 4
- Tumor stage ≥ T2b
- Known metastasis: N+ and/or M1
- General anesthesia or peridural anesthesia is not possible
- Coagulation disorder
Where
1 site, 1 recruiting
University Hospital
Erlangen, Germany
Potential match only. Final eligibility is determined by the study team.